Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Role of the immunosuppressive microenvironment in immunotherapy.

Tormoen GW, Crittenden MR, Gough MJ.

Adv Radiat Oncol. 2018 Oct 23;3(4):520-526. doi: 10.1016/j.adro.2018.08.018. eCollection 2018 Oct-Dec. Review.

2.

Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.

Baird JR, Bell RB, Troesch V, Friedman D, Bambina S, Kramer G, Blair TC, Medler T, Wu Y, Sun Z, de Gruijl TD, van de Ven R, Leidner RS, Crittenden MR, Gough MJ.

Cancer Res. 2018 Nov 1;78(21):6308-6319. doi: 10.1158/0008-5472.CAN-18-1652. Epub 2018 Sep 17.

PMID:
30224374
3.

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.

Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, Blair T, Baird JR, Alice A, Gough MJ.

Sci Rep. 2018 May 3;8(1):7012. doi: 10.1038/s41598-018-25482-w.

4.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

5.

Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity.

Alice AF, Kramer G, Bambina S, Baird JR, Bahjat KS, Gough MJ, Crittenden MR.

J Immunol. 2018 Jan 1;200(1):177-185. doi: 10.4049/jimmunol.1700909. Epub 2017 Nov 17.

PMID:
29150567
6.

STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0192988.

7.

Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Baird JR, Monjazeb AM, Shah O, McGee H, Murphy WJ, Crittenden MR, Gough MJ.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):362-373. doi: 10.1016/j.ijrobp.2017.04.014. Epub 2017 Apr 19. Review.

8.

Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. No abstract available.

PMID:
28202215
9.

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2016 Oct;61:166-76. doi: 10.1016/j.oraloncology.2016.08.020. Epub 2016 Sep 7. Review. Erratum in: Oral Oncol. 2017 Mar;66:e3.

PMID:
27614589
10.

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.

Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, Cottam B, Young K, Newell P, Nguyen C, Bambina S, Kramer G, Akporiaye E, Malecka A, Jackson A, Gough MJ.

Oncotarget. 2016 Nov 29;7(48):78653-78666. doi: 10.18632/oncotarget.11823.

11.

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR.

J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016.

12.

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.

Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ, Newell P.

Hepatol Res. 2017 Jun;47(7):702-714. doi: 10.1111/hepr.12789. Epub 2016 Sep 22.

PMID:
27501850
13.

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR.

PLoS One. 2016 Jun 9;11(6):e0157164. doi: 10.1371/journal.pone.0157164. eCollection 2016.

14.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
15.

Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma.

Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, Fox BA.

J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S107-15. doi: 10.1016/j.joms.2015.05.026. Review. No abstract available.

PMID:
26608138
16.

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ.

Cancer Res. 2016 Jan 1;76(1):50-61. doi: 10.1158/0008-5472.CAN-14-3619. Epub 2015 Nov 13.

17.

Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy.

Gough MJ, Crittenden MR, Young KH.

Immunotherapy. 2015;7(8):847-9. doi: 10.2217/IMT.15.58. Epub 2015 Aug 13. No abstract available.

PMID:
26268988
18.

Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice.

Crittenden MR, Savage T, Cottam B, Baird J, Rodriguez PC, Newell P, Young K, Jackson AM, Gough MJ.

Radiat Res. 2014 Aug;182(2):182-90. doi: 10.1667/RR13493.1. Epub 2014 Jul 3.

PMID:
24992164
19.

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor.

Crittenden MR, Savage T, Cottam B, Bahjat KS, Redmond WL, Bambina S, Kasiewicz M, Newell P, Jackson AM, Gough MJ.

PLoS One. 2013 Jul 25;8(7):e69527. doi: 10.1371/journal.pone.0069527. Print 2013.

20.

Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy.

Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ.

PLoS One. 2012;7(6):e39295. doi: 10.1371/journal.pone.0039295. Epub 2012 Jun 28.

21.

Immune system plays an important role in the success and failure of conventional cancer therapy.

Gough MJ, Crittenden MR.

Immunotherapy. 2012 Feb;4(2):125-8. doi: 10.2217/imt.11.157. No abstract available.

22.

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.

J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095.

23.

Combination approaches to immunotherapy: the radiotherapy example.

Gough MJ, Crittenden MR.

Immunotherapy. 2009 Nov;1(6):1025-37. doi: 10.2217/imt.09.64. Review.

PMID:
20635917
24.

Intratumoral immunotherapy: using the tumour against itself.

Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ.

Immunology. 2005 Jan;114(1):11-22. Review.

25.

Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity.

Gough MJ, Melcher AA, Crittenden MR, Sanchez-Perez L, Voellmy R, Vile RG.

Gene Ther. 2004 Jul;11(13):1099-104.

PMID:
15103319
26.

Macrophages orchestrate the immune response to tumor cell death.

Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, Ruchatz AN, Emiliusen LM, Vile RG.

Cancer Res. 2001 Oct 1;61(19):7240-7.

27.

Psychosocial consequences of bone marrow transplantation in donor and nondonor siblings.

Packman WL, Crittenden MR, Schaeffer E, Bongar B, Fischer JB, Cowan MJ.

J Dev Behav Pediatr. 1997 Aug;18(4):244-53.

PMID:
9276831
28.

Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation.

Kramer JH, Crittenden MR, DeSantes K, Cowan MJ.

Bone Marrow Transplant. 1997 Mar;19(6):607-13.

29.

Toxicities of total-body irradiation for pediatric bone marrow transplantation.

Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR, Swift PS, Cowan MJ, Wara WM.

Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):843-51.

PMID:
8598361
30.

The developmental implications of prenatal and/or postnatal crack cocaine exposure in preschool children: a preliminary report.

Bender SL, Word CO, DiClemente RJ, Crittenden MR, Persaud NA, Ponton LE.

J Dev Behav Pediatr. 1995 Dec;16(6):418-24; discussion 425-30.

PMID:
8746551
31.

A prospective study of cognitive functioning following low-dose cranial radiation for bone marrow transplantation.

Kramer JH, Crittenden MR, Halberg FE, Wara WM, Cowan MJ.

Pediatrics. 1992 Sep;90(3):447-50.

PMID:
1518705
32.

Physical growth and behavioral adaptations of children with renal insufficiency.

Crittenden MR, Holaday B.

ANNA J. 1989 Apr;16(2):87-92, 119.

PMID:
2774685
33.

Visibility of handicap, self-concept, and social maturity among young adult survivors of end-stage renal disease.

Beck AL, Nethercut GE, Crittenden MR, Hewins J.

J Dev Behav Pediatr. 1986 Apr;7(2):93-6.

PMID:
3700664
34.
35.

Intellectual development of children with renal insufficiency and end stage disease.

Crittenden MR, Holliday MA, Piel CF, Potter DE.

Int J Pediatr Nephrol. 1985 Oct-Dec;6(4):275-80.

PMID:
3912343
36.

Self-concept in the diethylstilbestrol daughter.

Shafer MA, Irwin CE Jr, Adler NE, Crittenden MR.

Obstet Gynecol. 1984 Jun;63(6):815-9.

PMID:
6728363
37.

Taking it day by day: when children undergo hemodialysis and renal transplantation.

Crittenden MR, Waechter E, Mikklesen CA.

Child Today. 1977 May-Jun;6(3):6-9, 35. No abstract available.

PMID:
328237

Supplemental Content

Loading ...
Support Center